Annual report [Section 13 and 15(d), not S-K Item 405]

Income Taxes

v3.25.2
Income Taxes
12 Months Ended
Jun. 30, 2025
Notes to Financial Statements  
Income Taxes

Note 12. Income Taxes:

Income before income taxes was comprised of the following (in thousands):

Year Ended June 30, 

    

2025

    

2024

    

2023

Domestic

$

86,814

$

174,806

$

288,458

Foreign

 

11,649

 

10,883

 

50,201

Earnings before income taxes

$

98,463

$

185,689

$

338,659

The provision for income taxes consisted of the following (in thousands):

Year Ended June 30, 

    

2025

    

2024

    

2023

Taxes on income consist of:

Current tax provision:

 

  

 

  

 

  

Federal

 

$

54,589

 

$

40,228

 

$

59,810

State

 

10,402

 

4,853

 

12,753

Foreign

 

11,224

 

12,664

 

10,453

Total current tax provision

 

76,215

 

57,745

 

83,016

Deferred tax provision:

 

  

 

  

 

  

Federal

 

(46,433)

 

(28,301)

 

(28,829)

State

 

(4,303)

 

(4,563)

 

(2,414)

Foreign

 

(416)

 

(7,297)

 

1,444

Total deferred tax provision

 

(51,152)

 

(40,161)

 

(29,799)

Total income tax provision

 

$

25,063

 

$

17,584

 

$

53,217

The Company’s discrete tax benefits in fiscal 2025, 2024, and 2023 primarily related to share-based compensation excess tax benefits of $4.5 million, $18.4 million, and $12.3 million, respectively.

The following is a reconciliation of the federal tax calculated at the statutory rate to the actual income taxes provided:

    

Year Ended June 30, 

    

2025

    

2024

    

2023

Income tax expense at federal statutory rate

21.0

%

 

21.0

%

 

21.0

%

State income taxes, net of federal benefit

2.2

 

(0.2)

 

2.5

Research and development tax credit

(3.3)

 

(2.2)

 

(1.3)

Foreign tax rate differences

6.2

 

3.1

 

(0.6)

Option exercises

(3.9)

 

(8.8)

 

(3.3)

U.S. taxation of foreign earnings

0.4

 

0.1

 

0.4

Foreign derived intangible income

(12.0)

 

(4.8)

 

(3.4)

Foreign withholding tax

0.1

(1.2)

1.5

Executive compensation limitations(1)

12.5

 

2.7

 

0.8

Changes in unrecognized tax benefits

(2.5)

Valuation allowance

17.4

Outside basis difference

(12.9)

Other, net

0.2

 

(0.2)

 

(1.9)

Effective tax rate

25.5

%

 

9.5

%

 

15.7

%

(1) This includes the impact of the non-deductible portion of a non-recurring arbitration award of 7.9%.

Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands):

June 30, 

    

2025

    

2024

Inventory

$

14,056

$

9,675

Net operating loss carryovers

 

26,758

 

25,065

Tax credit carryovers

 

8,706

 

9,118

Excess tax basis in investments

 

23,562

 

1,115

Deferred compensation

 

18,022

 

16,628

Lease liability

 

15,094

 

19,501

Capitalized R&D

39,694

36,151

Held-for-sale asset impairment

5,216

Derivatives

3,450

Other

 

10,196

 

6,119

Valuation allowance

 

(33,769)

 

(19,265)

Deferred tax assets

 

125,769

 

109,323

Intangible asset amortization

 

(84,113)

 

(120,648)

Depreciation

 

(19,287)

 

(20,448)

Right of use asset

 

(13,572)

 

(17,876)

Derivatives

(2,516)

Other

 

(4,659)

 

(3,698)

Deferred tax liabilities

 

(121,631)

 

(165,186)

Net deferred income tax assets (liabilities)

$

4,138

$

(55,863)

A deferred tax valuation allowance is required when it is more likely than not that all or a portion of deferred tax assets will not be realized. The valuation allowance as of June 30, 2025 was $33.8 million compared to $19.3 million in the prior year.

As of June 30, 2025, we had a $33.8 million valuation allowance, of which $13.1 million is from outside basis differences, with the remainder relating to certain foreign and state tax net operating loss and state credit carryforwards. The Company believes it is more likely than not that these tax carryovers will not be realized.

As of June 30, 2025, the Company has federal operating loss carryforwards of approximately $15.4 million and state operating loss carryforwards of $127.2 million from its previous acquisitions, which are not limited under IRC Section 382. As of June 30, 2025, the Company has foreign net operating loss carryforwards of $116.3 million. Some of the net operating loss carryforwards expire between fiscal 2026 and 2036. Federal net operating loss carryforwards generated after December 31, 2017 have an indefinite carryforward period but the Company expects to be fully utilize these attributes by June 30, 2032. The Company has a deferred tax asset of $10.5 million, net of the valuation allowance discussed above, related to the net operating loss carryovers. As of June 30, 2025, the Company has federal and state tax credit carryforwards of $4.9 million and $4.8 million, respectively. The federal tax credit carryforwards expire between 2028 and 2040. The majority of the state credit carryforwards have no expiry date. The state credit carryforwards that have expiry dates have a full valuation allowance. The Company has a deferred tax asset of $5.1 million, net of the valuation allowance discussed above, related to the tax credit carryovers.

As of June 30, 2025, the Company has approximately $179 million of undistributed earnings in its foreign subsidiaries. Approximately $73 million of these earnings are no longer considered permanently reinvested and the Company expects to be able to repatriate earnings on a tax neutral basis. The Company has not provided deferred taxes on approximately $106 million of undistributed earnings from non-U.S. subsidiaries as of June 30, 2025 which are indefinitely reinvested in operations. Because of the multiple entities as well as the complexities of laws and regulations by which to repatriate the earnings to minimize tax cost, it is not practical to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely. A deferred tax liability will be recognized if the Company can no longer demonstrate that it plans to indefinitely reinvest the undistributed earnings.

We continue to analyze our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries distribute cash to the U.S. parent, which include local country withholding tax and potential U.S. state taxation.

The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands):

Year Ended June 30, 

    

2025

    

2024

    

2023

Beginning balance

$

5,278

$

5,291

$

5,302

Decrease in unrecognized tax benefits for prior year positions

 

(1,950)

  

 

 

FX impact

1

(13)

(11)

Ending balances

$

3,329

$

5,278

$

5,291

Included in the balance of unrecognized tax benefits for fiscal 2025 are potential benefits of $3.3 million that, if recognized, would affect the effective tax rate on income from continuing operations. The Company recognizes interest and penalties related to unrecognized tax benefits in its provision for income taxes. The Company had $0.2 million of accrued interest and penalties as of June 30, 2025. The amount recorded for the periods ended June 30, 2024 and 2023, was $0.6 million and $0.5 million, respectively, in accrued interest and penalties. The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next twelve months. The Company files income tax returns in the U.S. federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Company’s federal returns are subject to tax assessment for 2020 and subsequent years. State and foreign income tax returns are generally subject to examination for a period of three to five years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to one year after formal notification to the states.